賽隆藥業(002898.SZ):擬參與競買珠海香洲商辦地 推進公司總部及研究院建設
格隆匯5月19日丨賽隆藥業(002898.SZ)公佈,子公司珠海賽隆國際投資有限公司擬參與競買項目地塊,宗地位置位於珠海市香洲區珠海大道南側、南灣大道西側;地塊面積為7977.66平方米;土地用途為商業性辦公用地;出讓年限40年;土地掛牌起始價為人民幣3.29億元。
此次參與競拍國有建設用地使用權是為了落實公司與珠海市香洲區投資促進服務中心簽訂的《項目投資協議書》及與中信城開簽訂的《總部項目合作協議》,推進公司總部及研究院建設。若競拍成功,對公司發展將起到積極的推動作用,有利於公司的持續長遠發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.